Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

 
• By Leah Samuel
Digital illustration of Cancer cell in colour background
Deciphera encouraged by overall survival data

More from Clinical Trials

More from R&D